Radioimmunotherapy (RIT) in non-Hodgkin lymphoma.
- Published in:
- Targeted Oncology, 2007, v. 2, n. 3, p. 173, doi. 10.1007/s11523-007-0057-2
- By:
- Publication type:
- Article
Works matching IS 17762596 AND DT 2007 AND VI 2 AND IP 3
Results: 8
1
2
Targeted therapy in advanced colorectal cancer, an update.
- Published in:
- Targeted Oncology, 2007, v. 2, n. 3, p. 165, doi. 10.1007/s11523-007-0052-7
- By:
- Publication type:
- Article
3
Role of the endothelins and endothelin receptors in cancer cell signaling and angiogenesis.
- Published in:
- Targeted Oncology, 2007, v. 2, n. 3, p. 181, doi. 10.1007/s11523-007-0056-3
- By:
- Publication type:
- Article
4
The mTOR pathway inhibitor RAD001 (everolimus) is highly efficacious in tamoxifen-sensitive and -resistant breast cancer xenografts.
- Published in:
- Targeted Oncology, 2007, v. 2, n. 3, p. 135, doi. 10.1007/s11523-007-0054-5
- By:
- Publication type:
- Article
5
Normalization, inhibition, rarefaction?
- Published in:
- 2007
- By:
- Publication type:
- Editorial
6
Reversible encephalopathy syndrome secondary to sunitinib for metastatic renal cell carcinoma patient.
- Published in:
- Targeted Oncology, 2007, v. 2, n. 3, p. 193, doi. 10.1007/s11523-007-0050-9
- By:
- Publication type:
- Article
7
Simple method to detect important epidermal growth factor receptor gene mutations with bronchoscopic specimens of lung cancer patients for gefitinib treatment.
- Published in:
- Targeted Oncology, 2007, v. 2, n. 3, p. 145, doi. 10.1007/s11523-007-0053-6
- By:
- Publication type:
- Article
8
VEGF: a key therapeutic target for the treatment of cancer-insights into its role and pharmacological inhibition.
- Published in:
- Targeted Oncology, 2007, v. 2, n. 3, p. 153, doi. 10.1007/s11523-007-0051-8
- By:
- Publication type:
- Article